BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17122642)

  • 1. Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: A feasibility study.
    Tubbs RR; Pettay JD; Swain E; Roche PC; Powell W; Hicks DG; Grogan T
    Appl Immunohistochem Mol Morphol; 2006 Dec; 14(4):436-40. PubMed ID: 17122642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the HER2 amplification status in oesophageal adenocarcinoma by conventional and automated FISH: a tissue microarray study.
    Prins MJ; Ruurda JP; van Diest PJ; van Hillegersberg R; ten Kate FJ
    J Clin Pathol; 2014 Jan; 67(1):26-32. PubMed ID: 24043715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of HER2 status in breast carcinoma by fully automated HER2 fluorescence in situ hybridization (FISH): comparison of two immunohistochemical tests and manual FISH.
    Yoon N; Do IG; Cho EY
    APMIS; 2014 Sep; 122(9):755-60. PubMed ID: 24372629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated processing of fluorescence in-situ hybridization slides for HER2 testing in breast and gastro-esophageal carcinomas.
    Tafe LJ; Allen SF; Steinmetz HB; Dokus BA; Cook LJ; Marotti JD; Tsongalis GJ
    Exp Mol Pathol; 2014 Aug; 97(1):116-9. PubMed ID: 24927872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A public-domain image processing tool for automated quantification of fluorescence in situ hybridisation signals.
    Konsti J; Lundin J; Jumppanen M; Lundin M; Viitanen A; Isola J
    J Clin Pathol; 2008 Mar; 61(3):278-82. PubMed ID: 17693574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists.
    Dietel M; Ellis IO; Höfler H; Kreipe H; Moch H; Dankof A; Kölble K; Kristiansen G
    Virchows Arch; 2007 Jul; 451(1):19-25. PubMed ID: 17562074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.
    Papouchado BG; Myles J; Lloyd RV; Stoler M; Oliveira AM; Downs-Kelly E; Morey A; Bilous M; Nagle R; Prescott N; Wang L; Dragovich L; McElhinny A; Garcia CF; Ranger-Moore J; Free H; Powell W; Loftus M; Pettay J; Gaire F; Roberts C; Dietel M; Roche P; Grogan T; Tubbs R
    Am J Surg Pathol; 2010 Jun; 34(6):767-76. PubMed ID: 20421783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.
    Shousha S; Peston D; Amo-Takyi B; Morgan M; Jasani B
    Histopathology; 2009 Jan; 54(2):248-53. PubMed ID: 19207950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of HER2 gene amplification using an automated fluorescence in situ hybridization signal enumeration system.
    Stevens R; Almanaseer I; Gonzalez M; Caglar D; Knudson RA; Ketterling RP; Schrock DS; Seemayer TA; Bridge JA
    J Mol Diagn; 2007 Apr; 9(2):144-50. PubMed ID: 17384205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
    Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer.
    Mansfield AS; Sukov WR; Eckel-Passow JE; Sakai Y; Walsh FJ; Lonzo M; Wiktor AE; Dogan A; Jenkins RB
    Am J Clin Pathol; 2013 Feb; 139(2):144-50. PubMed ID: 23355198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.
    Gao FF; Dabbs DJ; Cooper KL; Bhargava R
    Am J Clin Pathol; 2014 Jan; 141(1):102-10. PubMed ID: 24343743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer.
    Horii R; Matsuura M; Iwase T; Ito Y; Akiyama F
    Breast Cancer; 2014 Sep; 21(5):598-604. PubMed ID: 23307494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
    Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
    Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A; Bronsard M; Lemieux R; Geha S
    Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals.
    Jiang H; Bai X; Zhao T; Zhang C; Zhang X
    Oncol Rep; 2014 Nov; 32(5):1889-96. PubMed ID: 25119636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study.
    Franchet C; Filleron T; Cayre A; Mounié E; Penault-Llorca F; Jacquemier J; Macgrogan G; Arnould L; Lacroix-Triki M
    Histopathology; 2014 Jan; 64(2):274-83. PubMed ID: 24117939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays.
    Laurinaviciene A; Dasevicius D; Ostapenko V; Jarmalaite S; Lazutka J; Laurinavicius A
    Diagn Pathol; 2011 Sep; 6():87. PubMed ID: 21943197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.